Search

Displaying results 8711 - 8720 of 10000 in total
  1. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

    Synonyms: huMy9-6-DM4Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  2. Drug

    R-348

    go.drugbank.com/drugs/DB06321
    Investigational

    Synonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamine
  3. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

    Synonyms: ) (1-118) -HOMO SAPIENS IGHG1*01 (119-448)) (221-2, GAMMA1 HEAVY CHAIN (1-448) (MUS MUSCULUS VH (IGHV6-6*01-(IGHD) -IGHJ2*01) (8.10.9) (1-118) -HOMO SAPIENSIGHG1*01, GM17,1 (CH1 (119-216), HINGE (217-231), CH2(232-341), CH3 (342-446), CHS (447-448)) (119
  4. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  5. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

    Mixtures: KOMBIGLYZE ® XR 5 MG/ 1000 MG, Kombiglyze XR Tablet 5/500mgCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  7. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  9. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  10. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

    Mixtures: PHESGO® 600MG/600MG, PHESGO® 600MG/600MGCategories: Receptor, ErbB-2, antagonists & inhibitors, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors